Corresponding Author: Daniel M. Skovronsky, MD, PhD, Eli Lilly and Company, 893 Delaware St, Indianapolis, IN 46225 (skovronsky_daniel@lilly.com).
Accepted for Publication: January 8, 2021.
Published Online: January 21, 2021. doi:10.1001/jama.2021.0202
Author Contributions: Drs Gottlieb and Nirula had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Gottlieb and Nirula made equal contributions and are co–first authors.
Concept and design: Nirula, Huhn, Adams, Van Naarden, Custer, Durante, Sabo, Klekotka, Shen, Skovronsky.
Acquisition, analysis, or interpretation of data: Gottlieb, Nirula, Chen, Boscia, Heller, Morris, Huhn, Cardona, Mocherla, Stosor, Shawa, Kumar, Adams, Van Naarden, Custer, Durante, Oakley, Schade, Holzer, Ebert, Higgs, Kallewaard, Patel, Klekotka, Shen, Skovronsky.
Drafting of the manuscript: Gottlieb, Nirula, Adams, Oakley, Holzer, Sabo, Patel, Klekotka, Shen, Skovronsky.
Critical revision of the manuscript for important intellectual content: Gottlieb, Nirula, Chen, Boscia, Heller, Morris, Huhn, Cardona, Mocherla, Stosor, Shawa, Kumar, Adams, Van Naarden, Custer, Durante, Oakley, Schade, Holzer, Ebert, Higgs, Kallewaard, Sabo, Patel, Klekotka, Shen, Skovronsky.
Statistical analysis: Cardona, Adams, Durante, Higgs, Shen.
Obtained funding: Sabo.
Administrative, technical, or material support: Gottlieb, Morris, Huhn, Mocherla, Kumar, Adams, Oakley, Schade, Ebert, Kallewaard, Sabo, Patel, Klekotka.
Supervision: Gottlieb, Nirula, Huhn, Adams, Van Naarden, Custer, Sabo, Klekotka, Shen, Skovronsky.
Conflict of Interest Disclosures: Dr Gottlieb reported receiving personal fees and nonfinancial support (medication for another trial) from Gilead Sciences; and serving on an advisory board for Sentinel. Drs Nirula and Adams, Mr Van Naarden, Dr Custer, Mr Durante, and Drs Oakley, Schade, Holzer, Ebert, Higgs, Kallewaard, Sabo, Patel, Klekotka, Shen, and Skovronsky are all employees and shareholders of Eli Lilly and Company. Dr Chen reported receiving consulting fees from Eli Lilly and Company. Dr Boscia reported receiving honoraria for serving on the GlaxoSmithKline speakers bureau. Dr Huhn reported receiving grants and personal fees from Gilead, Viiv, and Janssen; receiving grants from Proteus and Bristol-Myers Squibb; and receiving personal fees from TheraTechnologies. Dr Kumar reported receiving grants and consulting fees from GlaxoSmithKline, Amgen, TheraTechnologies, Merck, and Gilead Sciences; and owning stock in GlaxoSmithKline, Johnson & Johnson, Merck, Gilead Sciences, and Pfizer. No other disclosures were reported.
Funding/Support: This trial was sponsored and funded by Eli Lilly and Company.
Role of the Funder/Sponsor: Eli Lilly and Company was responsible for the design of the clinical trial; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript. Eli Lilly and Company did not have the right to veto publication or to control the decision regarding to which journal the paper was submitted. All final content decisions were made by the authors.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank David McIlwain, PhD, medical writer and employee of Eli Lilly and Company, for writing and editorial support. The names of those who assisted in this program, including investigators and support staff, are listed in Supplement 1. In addition, we thank the patients and the network of mobile home health research nurses, whose contribution was vital to this project.
Additional Information: Bamlanivimab emerged from the collaboration between Eli Lilly and Company and AbCellera Biologics to create antibody therapies for the prevention and treatment of COVID-19. Eli Lilly and Company developed the antibody after it was discovered by AbCellera Biologics and scientists at the National Institute of Allergy and Infectious Diseases Vaccine Research Center. Etesevimab emerged from the collaboration among Eli Lilly and Company, Junshi Biosciences, and the Institute of Microbiology of the Chinese Academy of Sciences.
7.Li
L , Zhang
W , Hu
Y ,
et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial.
JAMA. 2020;324(5):460-470. Published correction appears in
JAMA. 2020;324(5):519. doi:
10.1001/jama.2020.10044PubMedGoogle ScholarCrossref 9.Chen
P , Nirula
A , Heller
B ,
et al; for the BLAZE-1 Investigators. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19.
N Engl J Med. Published online October 28, 2020. doi:
10.1056/NEJMoa2029849
Google Scholar 13.Jones
BE , Brown-Augsburger
PL , Corbett
KS ,
et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
bioRxiv. Published online October 9, 2020. doi:
10.1101/2020.09.30.318972
Google Scholar 17.Garg
S , Kim
L , Whitaker
M ,
et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1-30, 2020.
MMWR Morb Mortal Wkly Rep. 2020;69:458-464.
Google ScholarCrossref 18.Petrilli
CM , Jones
SA , Yang
J ,
et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study.
BMJ. 2020;369:m1966. doi:
10.1136/bmj.m1966PubMedGoogle ScholarCrossref 19.Ko
JY , Danielson
ML , Town
M ,
et al; COVID-NET Surveillance Team. Risk factors for COVID-19-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system.
Clin Infect Dis. Published online September 18, 2020. doi:
10.1093/cid/ciaa1419
PubMedGoogle Scholar